Baxdela
Total Payments
$2.2M
Transactions
20,431
Doctors
8,644
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $154,269 | 5 | 2 |
| 2023 | $99,150 | 2 | 1 |
| 2022 | $22,919 | 3 | 2 |
| 2021 | $56,939 | 127 | 79 |
| 2020 | $70,430 | 93 | 70 |
| 2019 | $748,419 | 7,982 | 4,080 |
| 2018 | $1.0M | 12,136 | 5,846 |
| 2017 | $4,550 | 83 | 83 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $725,438 | 349 | 33.4% |
| Unspecified | $616,340 | 33 | 28.4% |
| Food and Beverage | $476,270 | 19,188 | 21.9% |
| Consulting Fee | $181,037 | 81 | 8.3% |
| Travel and Lodging | $151,595 | 769 | 7.0% |
| Space rental or facility fees (teaching hospital only) | $14,675 | 3 | 0.7% |
| Honoraria | $4,500 | 3 | 0.2% |
| Education | $24.77 | 5 | 0.0% |
Payments by Type
General
$1.6M
20,398 transactions
Research
$616,340
33 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels | Melinta Therapeutics, LLC | $150,000 | 0 |
| 02-PRJ69JS | Melinta Therapeutics, Inc. | $89,000 | 0 |
| ML-3341-119 | Melinta Therapeutics, Inc. | $70,523 | 0 |
| DEFINE-CABP | Melinta Therapeutics, Inc. | $64,218 | 0 |
| In Vitro Activity of New Drug against Chlamydia Pneumoniae | Melinta Therapeutics, Inc. | $43,750 | 0 |
| The In-Vitro Activity of Delafloxacin and Comparator Agents Against Bacterial Pathogens Isolated from Patients with Cancer | Melinta Therapeutics, LLC | $42,633 | 0 |
| PA18-0968 | Melinta Therapeutics, Inc. | $21,316 | 0 |
| Comparison of In vitro Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials Against Isolates of Nontuberculous Mycobacteria | Melinta Therapeutics, Inc. | $18,006 | 0 |
| Delafloxacin Activity against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin or Linezolid | Melinta Therapeutics, LLC | $17,894 | 0 |
Top Doctors Receiving Payments for Baxdela — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Infectious Disease | Beeville, TX | $8,551 | 17 |
| , MD | Infectious Disease | Midland, TX | $8,475 | 16 |
| , M.D | Infectious Disease | Brookline, MA | $8,154 | 18 |
| , MD | Infectious Disease | San Diego, CA | $7,884 | 19 |
| , DO | Internal Medicine | Miami Beach, FL | $7,633 | 23 |
| , D.O | Emergency Medical Services | Oklahoma City, OK | $7,498 | 10 |
| , MD | Infectious Disease | Lake Mary, FL | $7,170 | 19 |
| , D.P.M | Podiatrist | Hermitage, GA | $7,108 | 37 |
| , M.D | Infectious Disease | Atlanta, GA | $6,822 | 14 |
| , M.D | Infectious Disease | Murrieta, CA | $6,735 | 21 |
| , MD | Hospitalist | San Antonio, TX | $6,250 | 24 |
| , DPM | Podiatrist | Nashville, TN | $5,997 | 11 |
| , MD | Pulmonary Disease | Chicago, IL | $5,623 | 4 |
| , MD | Internal Medicine | Detroit, MI | $5,352 | 1 |
| , M.D | Internal Medicine | Edinburg, TX | $5,099 | 13 |
| , D.O | Emergency Medicine | Colleyville, TX | $5,029 | 8 |
| , MD | Infectious Disease | Cookeville, TN | $4,827 | 23 |
| , MD | Infectious Disease | Indianapolis, IN | $4,530 | 12 |
| , M.D | Emergency Medicine | Phoenix, AZ | $4,377 | 8 |
| , MD | Internal Medicine | Oklahoma City, OK | $4,250 | 2 |
| , DPM | Podiatrist | Elk Grove Vlg, IL | $4,217 | 18 |
| , MD | Personal Emergency Response Attendant | N Las Vegas, NV | $3,935 | 19 |
| , MD | Critical Care Medicine | Roslyn, NY | $3,933 | 6 |
| , D.P.M | Foot & Ankle Surgery | Phoenixville, PA | $3,860 | 10 |
| , MD | Infectious Disease | West Jordan, UT | $3,495 | 11 |
Ad
Manufacturing Companies
- Melinta Therapeutics, Inc. $1.8M
- Melinta Therapeutics, LLC $391,458
- Hikma Pharmaceuticals USA $12,250
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 8,644
- Transactions 20,431
About Baxdela
Baxdela is a drug associated with $2.2M in payments to 8,644 healthcare providers, recorded across 20,431 transactions in the CMS Open Payments database. The primary manufacturer is Melinta Therapeutics, Inc..
Payment data is available from 2017 to 2024. In 2024, $154,269 was paid across 5 transactions to 2 doctors.
The most common payment nature for Baxdela is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($725,438, 33.4% of total).
Baxdela is associated with 9 research studies, including "In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels" ($150,000).